Study Chair
Matt Mandel, MD
BioXcel Therapeutics
- 2 trials
- 1 compound
Therapeutic focus
- Bipolar I Disorder
- Bipolar II Disorder
- Schizophrenia
- Schizoaffective Disorder
- Schizophreniform Disorders
- Psychomotor Agitation
- Agitation
- Schizophreniform Disorder
All trials (2)
| NCT | Phase | Status | Compound | Sponsor |
|---|---|---|---|---|
| NCT07116694 | Phase 2 | Completed | — | BioXcel Therapeutics Inc |
| NCT05658510 | Phase 3 | Completed | Dexmedetomidine sublingual film (BXCL501) | BioXcel Therapeutics, Inc. |
Compounds studied
Trial sites (24)
- Las Vegas, Nevada, United States
- Culver City, California, United States
- Bellflower, California, United States
- Austin, Texas, United States
- Miami, Florida, United States
- Riverside, California, United States
- Los Angeles, California, United States
- Cerritos, California, United States
- Oceanside, California, United States
- DeSoto, Texas, United States
- Everett, Washington, United States
- Lemon Grove, California, United States
- Beachwood, Ohio, United States
- Plano, Texas, United States
- Denver, Colorado, United States
- Rancho Cucamonga, California, United States
- Chino, California, United States
- St Louis, Missouri, United States
- Garden Grove, California, United States
- Irving, Texas, United States
- Gaithersburg, Maryland, United States
- Berlin, New Jersey, United States
- Elgin, Illinois, United States
- Orange, California, United States
Investigator and site data mirrored fromClinicalTrials.gov (public domain).